Post-Conference Perspectives: RxPONDER, SABCS 2020

Experts in breast cancer provide a historic perspective on the use of the Oncotype DX recurrence score (RS) in patients with HR+, HER- breast cancer and review practical implications from the TAILORx trial.

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, review recent results from the RxPONDER trial looking at the predictive value of the Oncotype DX RS on benefit of adjuvant chemotherapy in women with lymph node-positive, HR+, HER2- breast cancer.

The practice-changing results and implications from the RxPONDER trial for early-stage HR+ breast cancer is discussed.

Experts in breast cancer comment on NCCN guideline recommendations as they reflect the outcomes of the RxPONDER trial for HR+ early breast cancer.

Questions to consider when approaching the treatment of HR+, HER2-breast cancer based on the RxPONDER trial results.

Lajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.